Cargando…
Optogenetics: implications for Alzheimer’s disease research and therapy
Alzheimer’s disease (AD), a critical neurodegenerative condition, has a wide range of effects on brain activity. Synaptic plasticity and neuronal circuits are the most vulnerable in Alzheimer’s disease, but the exact mechanism is unknown. Incorporating optogenetics into the study of AD has resulted...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867657/ https://www.ncbi.nlm.nih.gov/pubmed/35197102 http://dx.doi.org/10.1186/s13041-022-00905-y |
_version_ | 1784656097582252032 |
---|---|
author | Mirzayi, Parsa Shobeiri, Parnian Kalantari, Amirali Perry, George Rezaei, Nima |
author_facet | Mirzayi, Parsa Shobeiri, Parnian Kalantari, Amirali Perry, George Rezaei, Nima |
author_sort | Mirzayi, Parsa |
collection | PubMed |
description | Alzheimer’s disease (AD), a critical neurodegenerative condition, has a wide range of effects on brain activity. Synaptic plasticity and neuronal circuits are the most vulnerable in Alzheimer’s disease, but the exact mechanism is unknown. Incorporating optogenetics into the study of AD has resulted in a significant leap in this field during the last decades, kicking off a revolution in our knowledge of the networks that underpin cognitive functions. In Alzheimer's disease, optogenetics can help to reduce and reverse neural circuit and memory impairments. Here we review how optogenetically driven methods have helped expand our knowledge of Alzheimer's disease, and how optogenetic interventions hint at a future translation into therapeutic possibilities for further utilization in clinical settings. In conclusion, neuroscience has witnessed one of its largest revolutions following the introduction of optogenetics into the field. |
format | Online Article Text |
id | pubmed-8867657 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88676572022-02-28 Optogenetics: implications for Alzheimer’s disease research and therapy Mirzayi, Parsa Shobeiri, Parnian Kalantari, Amirali Perry, George Rezaei, Nima Mol Brain Review Alzheimer’s disease (AD), a critical neurodegenerative condition, has a wide range of effects on brain activity. Synaptic plasticity and neuronal circuits are the most vulnerable in Alzheimer’s disease, but the exact mechanism is unknown. Incorporating optogenetics into the study of AD has resulted in a significant leap in this field during the last decades, kicking off a revolution in our knowledge of the networks that underpin cognitive functions. In Alzheimer's disease, optogenetics can help to reduce and reverse neural circuit and memory impairments. Here we review how optogenetically driven methods have helped expand our knowledge of Alzheimer's disease, and how optogenetic interventions hint at a future translation into therapeutic possibilities for further utilization in clinical settings. In conclusion, neuroscience has witnessed one of its largest revolutions following the introduction of optogenetics into the field. BioMed Central 2022-02-23 /pmc/articles/PMC8867657/ /pubmed/35197102 http://dx.doi.org/10.1186/s13041-022-00905-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Mirzayi, Parsa Shobeiri, Parnian Kalantari, Amirali Perry, George Rezaei, Nima Optogenetics: implications for Alzheimer’s disease research and therapy |
title | Optogenetics: implications for Alzheimer’s disease research and therapy |
title_full | Optogenetics: implications for Alzheimer’s disease research and therapy |
title_fullStr | Optogenetics: implications for Alzheimer’s disease research and therapy |
title_full_unstemmed | Optogenetics: implications for Alzheimer’s disease research and therapy |
title_short | Optogenetics: implications for Alzheimer’s disease research and therapy |
title_sort | optogenetics: implications for alzheimer’s disease research and therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867657/ https://www.ncbi.nlm.nih.gov/pubmed/35197102 http://dx.doi.org/10.1186/s13041-022-00905-y |
work_keys_str_mv | AT mirzayiparsa optogeneticsimplicationsforalzheimersdiseaseresearchandtherapy AT shobeiriparnian optogeneticsimplicationsforalzheimersdiseaseresearchandtherapy AT kalantariamirali optogeneticsimplicationsforalzheimersdiseaseresearchandtherapy AT perrygeorge optogeneticsimplicationsforalzheimersdiseaseresearchandtherapy AT rezaeinima optogeneticsimplicationsforalzheimersdiseaseresearchandtherapy |